Are Your Menopausal Patients at Metabolic Risk 

What lies beneath the sheen of sweat on your patient’s perimenopausal forehead might be much more than a hot flash. Metabolic syndrome, a kaleidoscope of midlife clinical issues, could be hiding in plain sight.  

Left unchecked, increases in blood sugar, cholesterol, blood pressure, and visceral fat are highly likely after menopause. Any one of these problems is cause for concern; a formal diagnosis of three or more can place women in danger of developing heart disease, type II diabetes, and stroke.  

It’s estimated postmenopausal women have a 60% increased risk of developing metabolic syndrome. Some signs are obvious. Patients struggling with obesity may raise a few clinical flags, but a silent killer like high blood pressure can hardly be picked out of a lineup. Most warning signs are invisible. 

Research associating menopause and unfavorable health changes are on the rise. Losses in estradiol (E2), women’s metabolic health hero, appears to be leading the charge. When estradiol and testosterone are plentiful, they pack a serious metabolic punch. During perimenopause and beyond, the metabolic markers below take a hit when levels slip.  

Risk: Menopause is associated with midsection fat accumulation. This fat is metabolically active and can lead to increased likelihood for obesity and high blood pressure. 

Hormonal Significance: 

• Body shape changes are connected to E2 decline. Estradiol can inhibit visceral fat tissue development while supporting lipid homeostasis. 

• Testosterone therapy can increase lean mass via improved bone density and muscle mass while positively impacting basal metabolic rate. 

Risk: Glucose metabolism and insulin sensitivity are jeopardized during menopause. Lipid parameters are negatively affected, as LDL cholesterol and triglycerides often increase. 

Hormonal Significance: 

• Both testosterone and estradiol increase muscle insulin sensitivity. As an anti-diabetic hormone, estradiol supports insulin secretion and pancreatic B-cell function. It can reduce insulin resistance in postmenopausal patients, limiting risk of type II DM development.  

• Research shows that estradiol therapy may help reduce the ratio of LDL/HDL cholesterol, promoting cardiovascular health. 

Risk: Women between the ages of 45 and 64, a snapshot of peri and post menopause, are at greater likelihood of developing hypertension than men of similar age. Roughly 75% of postmenopausal women over the age of 60 have high blood pressure.    

Hormonal Significance:  

• Estradiol offers protection of the vasculature, promoting vasodilation and flexibility crucial for managing blood pressure. It’s thought to be cardioprotective, involved in limiting oxidative stress and inflammation. 

Despite overwhelming evidence to support menopause as a catalyst for cardiometabolic change, some health professionals are as confused as ever when it comes to hormonal intervention. In truth, published studies are complicated. Authors are often conflicted. It’s no secret why — menopausal hormone therapy (MHT), a phrase thrown around in the literature, is misleading.  

In terms of estrogen, MHT can mean anything from conjugated equine estrogen (CEE) to 17-B estradiol. One is a synthetic hormone, not native to the body (CEE). The other, 17-B estradiol, is bioidentical. It has the same chemical structure as what the body naturally produces. Same goes for medroxyprogesterone (synthetic) and micronized progesterone (bioidentical). Grouping them together confounds the reader. It’s like looking to clinical trials performed exclusively in men to inform the scientific community about women. Study after study reveals that the clinical outcomes are not the same, because distinct chemical entities often elicit different effects.  

While some providers understand the difference, many are stuck. Some feel the juice isn’t worth the squeeze, ignoring the monumental benefits BHRT can offer metabolic health.  

For more than 75 million women in perimenopause, the clock is ticking. Recent research points to the importance of therapeutic timing. Prescribing individualized hormone support in women under the age of 60 who are perimenopausal or recently postmenopausal can soften the physiologic blow of not only estrogen loss, but of greater hormonal imbalance.  

Where does that leave women? Put simply, at risk. Cardiovascular disease and diabetes are complex medical conditions, requiring significant management. No one is suggesting a simple solution. But if bioidentical hormone replacement could help turn the metabolic tide, consider their therapeutic potential. 

References 

1. Cho YH, Lee SY. Effect of Postmenopausal Hormone Therapy on Metabolic Syndrome and Its Components. J Clin Med. 2024 Jul 10;13(14):4043. doi: 10.3390/jcm13144043. PMID: 39064084; PMCID: PMC11277411. 
   
2. Ghazi L, Bello NA. Hypertension in Women Across the Lifespan. Curr Atheroscler Rep. 2021 Jun 19;23(8):43. doi: 10.1007/s11883-021-00941-4. PMID: 34146177; PMCID: PMC8299318. 
   
3. Hodis HN, Mack WJ. Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing. Cancer J. 2022 May-Jun 01;28(3):208-223. doi: 10.1097/PPO.0000000000000591. PMID: 35594469; PMCID: PMC9178928. 
   
4. Mahboobifard F, Pourgholami MH, Jorjani M, Dargahi L, Amiri M, Sadeghi S, Tehrani FR. Estrogen as a key regulator of energy homeostasis and metabolic health. Biomed Pharmacother. 2022 Dec;156:113808. doi: 10.1016/j.biopha.2022.113808. Epub 2022 Oct 15. PMID: 36252357. 
   
5. Mauvais-Jarvis F, Lindsey SH. Metabolic benefits afforded by estradiol and testosterone in both sexes: clinical considerations. J Clin Invest. 2024 Sep 3;134(17):e180073. doi: 10.1172/JCI180073. PMID: 39225098; PMCID: PMC11364390. 
   
6. Opoku AA, Abushama M, Konje JC. Obesity and menopause. Best Pract Res Clin Obstet Gynaecol. 2023 Jun;88:102348. doi: 10.1016/j.bpobgyn.2023.102348. Epub 2023 May 6. PMID: 37244787. 
   
7. Ou YJ, Lee JI, Huang SP, Chen SC, Geng JH, Su CH. Association between Menopause, Postmenopausal Hormone Therapy and Metabolic Syndrome. J Clin Med. 2023 Jun 30;12(13):4435. doi: 10.3390/jcm12134435. PMID: 37445470; PMCID: PMC10342857. 
   
8. Samargandy S, Matthews KA, Brooks MM, Barinas-Mitchell E, Magnani JW, Thurston RC, El Khoudary SR. Trajectories of Blood Pressure in Midlife Women: Does Menopause Matter? Circ Res. 2022 Feb 4;130(3):312-322. doi: 10.1161/CIRCRESAHA.121.319424. Epub 2022 Jan 6. PMID: 35113663; PMCID: PMC8814466.